Compare MPTI & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPTI | AKBA |
|---|---|---|
| Founded | 1965 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.9M | 375.0M |
| IPO Year | 2022 | 2014 |
| Metric | MPTI | AKBA |
|---|---|---|
| Price | $72.60 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $71.00 | $4.67 |
| AVG Volume (30 Days) | 62.7K | ★ 2.9M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $54,417,000.00 | N/A |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $12.15 | N/A |
| P/E Ratio | $29.41 | ★ N/A |
| Revenue Growth | ★ 11.03 | N/A |
| 52 Week Low | $36.38 | $1.13 |
| 52 Week High | $87.23 | $4.08 |
| Indicator | MPTI | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 37.84 |
| Support Level | $60.13 | $1.16 |
| Resistance Level | $79.58 | $1.56 |
| Average True Range (ATR) | 4.06 | 0.07 |
| MACD | 1.23 | -0.03 |
| Stochastic Oscillator | 50.16 | 18.07 |
M-Tron Industries Inc is an electronic components manufacturer based in the United States. Along with its subsidiaries, the company is engaged in designing, manufacturing, and marketing high-engineered, high-reliability frequency and spectrum control products used to control the frequency or timing of signals in electronic circuits in various applications. The company serves markets in aerospace and defense, space, and avionics sectors. Its product offerings include microwave and millimeter-wave filters, crystal resonators, clock oscillators, voltage-controlled crystal oscillators, low noise amplifiers, couplers, attenuators, and switches, among others. Geographically, it derives maximum revenue from the domestic market, and the rest from Malaysia, Australia, Greece, and other countries.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.